Phase II of Erlotinib an Epidermal Growth Factor Receptor Inhibitor in the Treatment of Myelodysplastic Syndrome.
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 25 Nov 2014
At a glance
- Drugs Erlotinib (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- 01 May 2009 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 31 Dec 2007 New trial record.